TABLE 2.
Validation of multiplex PCR assay with well-characterized clinical control strains
| Groupa | Total no. of isolates tested | Phenotypeb (OXA susceptibility) | Single-target PCRc
|
Triplex PCRc
|
Correlation (%) | |||
|---|---|---|---|---|---|---|---|---|
| PVL | mecA | 16S rRNA | PVL | mecA | ||||
| PVL (−) MSSA | 30 | S | − | − | + | − | − | 100 |
| PVL (+) MSSA | 13 | S | + | − | + | + | − | 100 |
| PVL (−) MRSA | 30 | R | − | + | + | − | + | 100 |
| PVL (+) MRSA | 45 | R | + | + | + | + | + | 100 |
| PVL (−) MS-CoNS | 30 | S | − | − | + | − | − | 100 |
| PVL (−) MR-CoNS | 30 | R | − | + | + | − | + | 100 |
a
PVL (−), PVL negative; PVL (+), PVL positive.
b
Oxacillin (OXA) susceptibility was determined with the VITEK system (bioMerieux) and by oxacillin susceptibility screening; S, susceptible; R, resistant (see Table 1 for details).
c
16S rRNA, Staphylococcus genus specific; lukS/F-PV genes encode Panton-Valentin leukocidin S/F proteins; mecA, determinant of methicillin resistance; +, positive for gene; −, negative for gene.